Improving Safety of Antivenom in People Bitten by Snakes
Completed
University of Kelaniya
Phase 4
2005-03-01
A study to increase the safety of polyvalent antivenom involving 1000 patients in three
centres: low dose adrenaline, promethazine, & hydrocortisone (alone and in combination) to
prevent acute adverse reactions to antivenom in people bitten by snakes: randomised, double
blind, placebo-controlled trial.
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Terminated
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1
2006-02-01
This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked
to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen.
The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of
111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]),
with secondary objectives of determining changes in tumor metabolism and describing the
antitumor responses to CMD-193.
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Terminated
Ludwig Institute for Cancer Research
Phase 1
2006-02-01
This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked
to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen.
The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of
111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]),
with secondary objectives of determining changes in tumor metabolism and describing the
antitumor responses to CMD-193.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
